Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15;21(1):418.
doi: 10.1186/s12885-021-08161-4.

The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma

Xuyang Ma  1 , Ying Ding  2 , Li Zeng  3
Affiliations

The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma

Xuyang Ma et al. BMC Cancer. .

Abstract

Background: The potential correlation between H2AFY (also known as MacroH2A1) and the clinical characteristics of hepatocellular carcinoma (HCC) patients was analysed through gene expression profiles and clinical data in The Cancer Genome Atlas (TCGA) database, and the diagnostic and prognostic value of H2AFY in HCC was discussed.

Methods: The gene expression data of HCC and the corresponding clinical characteristics of HCC patients were downloaded from the TCGA database. The differences in H2AFY in normal liver tissues and HCC were analysed. The relationship between H2AFY and clinical characteristics was analysed by Wilcoxon signed-rank test, logistic regression and Kruskal-Wallis test. The Kaplan-Meier method and the Cox regression method were used to analyse the relationship between overall survival and clinical characteristics of the patients. An ROC curve was used to predict the diagnostic value of H2AFY in HCC. Gene set enrichment analysis (GSEA) was used to analyse the pathway enrichment of H2AFY.

Result: Compared with normal liver tissues, H2AFY was significantly highly expressed in HCC. H2AFY was positively correlated with the age, clinical stage, G stage (grade) and T stage (tumor stage) of liver cancer patients. Higher H2AFY expression predicted a poor prognosis in HCC patients. Cox regression analysis suggested that H2AFY was an independent risk factor for the prognosis of HCC patients. The ROC curve suggested that H2AFY had certain diagnostic value in HCC. GSEA suggested that H2AFY was correlated with lipid metabolism and a variety of tumour pathways.

Conclusion: Our study showed that H2AFY was significantly overexpressed in HCC. H2AFY may be a potential diagnostic and prognostic marker for HCC, and high expression of H2AFY predicts a poor prognosis in patients with HCC.

Keywords: Bioinformatics; H2AFY; Hepatocellular carcinoma; MacroH2A1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The expression level of H2AFY in HCC and normal liver tissues. H2AFY is more highly expressed in HCC compared with normal liver tissues
Fig. 2
Fig. 2
The relationship between H2AFY expression and clinical characteristics. a. age. b clinical stage. c grade. d tumor stage. e lymph node metastasis. f distant metastases. g sex
Fig. 3
Fig. 3
The forest plot shows the multivariate analysis of the relationship between H2AFY expression and overall survival among HCC patients
Fig. 4
Fig. 4
The relationship between H2AFY expression and overall survival in HCC patients
Fig. 5
Fig. 5
The ROC curve demonstrated the diagnostic value of H2AFY in HCC patients
Fig. 6
Fig. 6
Enrichment plots from gene set enrichment analysis (GSEA)
Fig. 7
Fig. 7
Enrichment plots from gene set enrichment analysis (GSEA)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oikawa T. Cancer stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology. 2016;64(2):645–651. doi: 10.1002/hep.28485. - DOI - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi: 10.1016/S0140-6736(18)30010-2. - DOI - PubMed
    1. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. doi: 10.1111/j.1365-2036.2009.04014.x. - DOI - PMC - PubMed
    1. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108(3):425–432. doi: 10.1038/ajg.2012.449. - DOI - PMC - PubMed
    1. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118. doi: 10.1053/j.gastro.2009.04.005. - DOI - PMC - PubMed

MeSH terms